title: [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].
abstract: The aim of this study was to evaluate efavirenz and nevirapine plasma levels in HIV-infected hemophilic patients seen in two hospitals in Barcelona. Plasma levels of these drugs were determined by high-performance liquid chromatography (HPLC) at four-month intervals, together with viral load and CD4 cell count. Nineteen patients treated with efavirenz and 8 with nevirapine were included, and 68 efavirenz and 31 nevirapine determinations were performed. Mean study time was 12 months. Median efavirenz plasma concentration was 2.95 .g/ml (interval: 1.54-5.26 .g/ml) in patients with favorable virological response and 1.86 .g/ml (0.82-4.88 .g/ml) in patients with detectable viral load (p = 0.32). Nevirapine plasma concentrations were 4.41 .g/ml (3.50-6.72 .g/ml) and 3.12 .g/ml (2.44-3.80 .g/ml) respectively (p = 0.18).
authors.affiliation: Unidad de Hemofilia, Servicio de Farmacia, Hospital Universitario Vall d'Hebron, Barcelona, Spain. mmartore@vhebron.net
authors.forename: Marta
authors.initials: M
authors.lastname: Martorell
authors.forename: Rosa M
authors.initials: RM
authors.lastname: López
authors.forename: Esteban
authors.initials: E
authors.lastname: Ribera
authors.forename: Isabel
authors.initials: I
authors.lastname: Ruiz
authors.forename: Cristina
authors.initials: C
authors.lastname: Tural
authors.forename: Lluís
authors.initials: L
authors.lastname: Puig
authors.forename: Josep
authors.initials: J
authors.lastname: Monterde
mesh_terms: D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D000963:Antimetabolites / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006467:Hemophilia A / Q000097:blood* / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D013030:Spain; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D000963:Antimetabolites; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz